Gulf International Bank UK Ltd Has $2.22 Million Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Gulf International Bank UK Ltd reduced its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 3.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,555 shares of the biotechnology company’s stock after selling 213 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Axon Enterprise were worth $2,219,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in AXON. Motley Fool Asset Management LLC grew its holdings in Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of Axon Enterprise in the first quarter worth $81,630,000. International Assets Investment Management LLC bought a new position in Axon Enterprise during the third quarter worth $871,860,000. Vanguard Group Inc. raised its stake in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the last quarter. Finally, Swedbank AB bought a new stake in Axon Enterprise in the 1st quarter valued at $39,923,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $459.52 on Thursday. The stock has a market capitalization of $34.73 billion, a price-to-earnings ratio of 121.25, a P/E/G ratio of 10.99 and a beta of 0.94. The firm’s 50-day moving average price is $405.32 and its two-hundred day moving average price is $343.13. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 1-year low of $212.88 and a 1-year high of $462.64.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same period in the prior year, the company earned $0.80 EPS. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. On average, equities analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on AXON. Robert W. Baird boosted their price objective on shares of Axon Enterprise from $440.00 to $460.00 and gave the stock an “outperform” rating in a report on Monday. Jefferies Financial Group initiated coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Barclays raised their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities boosted their price objective on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Finally, Bank of America began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price for the company. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $392.85.

Insider Transactions at Axon Enterprise

In related news, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now directly owns 7,379 shares in the company, valued at approximately $2,752,588.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 371,172 shares of company stock worth $137,000,162. Insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.